person · Reporting owner

Zurbay Donald

Disclosed activity across 7 companies

Tapewire entity: 37172
SEC CIK: 0001341608

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
DENTSPLY SIRONA Inc.XRAY · Entity 4448	Director	June 03, 2026	June 05, 2026
LivaNova PLCLIVN · Entity 507	Director	June 15, 2026	June 17, 2026
Sight Sciences, Inc.SGHT · Entity 5537	Director	June 04, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

DENTSPLY SIRONA Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,693	Reported balance After 2026-06-03 transaction · row 1 1 source row Row 1 · 2026-06-03 · Grant · Acquired 22,822 · Balance 29,693 F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This grant consists entirely of Restricted Stock Units (RSUs) that vest in full (restrictions lapse) one year from date of grant.

LivaNova PLC

Report date June 15, 2026 · Filed June 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	2,252	Ending reported balance After 2026-06-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-15 · Exercise / conversion · Acquired 2,560 · Balance 2,560 F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value. F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. Row 2 · 2026-06-15 · Tax withholding · Disposed 308 · Balance 2,252 F3: Shares withheld to satisfy tax liability.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-15 · Exercise / conversion · Disposed 2,560 · Balance 0 F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F4: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,383	Reported balance After 2026-06-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-15 · Grant · Acquired 2,383 · Balance 2,383 F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement. F5: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), 1.00 GBP par value.

F2: Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the Company's 2025 Director Incentive Award Plan (the 2025 Plan) and the 2025 Plan award agreement.

F3: Shares withheld to satisfy tax liability.

F4: RSUs granted under the 2025 Plan on September 15, 2025 that vested on June 15, 2026.

F5: The RSUs, granted under the 2025 Plan, vest on June 15, 2027, subject to continued service during the vesting period and the terms of the 2025 Plan award agreement.

Sight Sciences, Inc.

Report date June 04, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	193,613	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 28,261 · Balance 193,613 F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2: Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

F2: Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVEDRO INC

Report date November 21, 2019 · Filed November 25, 2019

Section 16 reporting ended · disclosed 2019-11-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-21 transaction · row 1 1 source row Row 1 · 2019-11-21 · Disposition to issuer · Disposed 3,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2029-01-08	Direct	Reported balance After 2019-11-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-21 · Disposition to issuer · Disposed 8,314 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2027-06-26	Direct	Reported balance After 2019-11-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-21 · Disposition to issuer · Disposed 41,941 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.69 · Expires 2028-07-17	Direct	Reported balance After 2019-11-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-21 · Disposition to issuer · Disposed 10,224 · Balance 0 F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2019-11-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-21 · Disposition to issuer · Disposed 3,005 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share.

F2: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU.

PATTERSON COMPANIES, INC.

Report date April 17, 2025 · Filed April 17, 2025

Section 16 reporting ended · disclosed 2025-04-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-04-17 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2025-04-17 · Grant · Acquired 20,840 · Balance 243,576 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F2: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2022 and held by the Reporting Person immediately prior to the closing of the Merger. Row 2 · 2025-04-17 · Grant · Acquired 60,132 · Balance 303,708 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F3: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2023 and held by the Reporting Person immediately prior to the closing of the Merger. Row 3 · 2025-04-17 · Grant · Acquired 94,477 · Balance 398,185 F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement). F4: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2024 and held by the Reporting Person immediately prior to the closing of the Merger. Row 4 · 2025-04-17 · Disposition to issuer · Disposed 398,185 · Balance 0 F5: Includes an aggregate 131,233 restricted stock units awarded to the Reporting Person pursuant to the Plan in the years 2022 through 2024 and held by the Reporting Person immediately prior to the closing of the Merger. F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger.
Common StockSEC Table I · non-derivative	IndirectBy KSOP	Reported balance After 2025-04-17 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2025-04-17 · Disposition to issuer · Disposed 1,243 · Balance 0 F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger. F7: Represents Shares indirectly held by the Reporting Person's Employee Stock Ownership Plan component of their 401(k) (the "KSOP") account immediately prior to the closing of the Merger.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.26 · Expires 2033-07-01	Direct	Reported balance After 2025-04-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-17 · Disposition to issuer · Disposed 93,633 · Balance 0 F8: Stock options granted pursuant to the Plan on 7/1/2023. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F9: This option, which vested 33.3% on 7/1/2024, and was originally scheduled to vest 33.3% on 7/1/2025 and 33.4% on 7/1/2026, was cancelled for no consideration, because the exercise price was greater than the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.99 · Expires 2032-12-05	Direct	Reported balance After 2025-04-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-17 · Disposition to issuer · Disposed 134,033 · Balance 0 F11: Stock options granted pursuant to the Plan on 12/5/2022. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F12: This option, which vested 33.3% on 12/5/2023, 33.3% on 12/5/2024 and was originally scheduled to vest 33.4% on 12/5/2025, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.59 · Expires 2032-07-01	Direct	Reported balance After 2025-04-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-17 · Disposition to issuer · Disposed 35,895 · Balance 0 F13: Stock options granted pursuant to the Plan on 7/1/2022. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F14: This option, which vested 33.3% on 7/1/2023, 33.3% on 7/1/2024 and was originally scheduled to vest 33.4% on 7/1/2025, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.77 · Expires 2031-07-01	Direct	Reported balance After 2025-04-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-17 · Disposition to issuer · Disposed 37,831 · Balance 0 F15: Stock options granted pursuant to the Plan on 7/1/2021. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F16: This option, which vested 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $23.57 · Expires 2030-07-14	Direct	Reported balance After 2025-04-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-17 · Disposition to issuer · Disposed 57,819 · Balance 0 F17: Stock options granted pursuant to the Plan on 7/14/2020. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F18: This option, which vested 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.25 · Expires 2029-07-01	Direct	Reported balance After 2025-04-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-04-17 · Disposition to issuer · Disposed 78,829 · Balance 0 F19: Stock options granted pursuant to the Plan on 7/1/2019. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F20: This option, which vested 33.3% on 7/1/2020, 33.3% on 7/1/2021 and 33.4% on 7/1/2022, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.48 · Expires 2028-07-01	Direct	Reported balance After 2025-04-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-04-17 · Disposition to issuer · Disposed 33,363 · Balance 0 F21: Stock options granted pursuant to the Plan on 7/1/2018. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F22: This option, which vested 100% on 7/1/2021, was cancelled and exchanged for Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.67 · Expires 2028-06-29	Direct	Reported balance After 2025-04-17 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-04-17 · Disposition to issuer · Disposed 99,250 · Balance 0 F23: Stock options granted as an inducement award granted outside the Plan on 6/29/2018. F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration. F24: This option, which vested pro-rata over the course of 3 years, with one-third of the shares vesting on 6/29/2019, one-third vesting on 6/29/2020, and the remaining one-third vesting on 6/29/2021, in all cases subject to continued employment, was cancelled and exchanged for Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Performance share units ("PSUs") granted pursuant to the Patterson Companies, Inc. ("Patterson") Amended and Restated 2015 Omnibus Incentive Plan (the "Plan") and held by the Reporting Person immediately prior to the closing of the Merger (as defined below) vested pursuant to the Merger Agreement (as defined below) (with performance-based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance (without application of any modifier) as set forth in the applicable PSU award agreement).

F2: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2022 and held by the Reporting Person immediately prior to the closing of the Merger.

F3: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2023 and held by the Reporting Person immediately prior to the closing of the Merger.

F4: Represents vesting of PSUs that were granted to the Reporting Person pursuant to the Plan on 7/1/2024 and held by the Reporting Person immediately prior to the closing of the Merger.

F5: Includes an aggregate 131,233 restricted stock units awarded to the Reporting Person pursuant to the Plan in the years 2022 through 2024 and held by the Reporting Person immediately prior to the closing of the Merger.

F6: Reflects the disposition of shares of common stock, par value $0.01 per share ("Shares"), of Patterson in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of December 10, 2024 (the "Merger Agreement"), by and among Patterson, Paradigm Parent, LLC, a Delaware limited liability company ("Parent"), and Paradigm Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Parent ("Merger Sub"). On April 17, 2025, upon the closing of the merger of Merger Sub with and into Patterson (the "Merger") contemplated by the Merger Agreement, each outstanding Share was cancelled and automatically converted into the right to receive $31.35 in cash, without interest, and minus any applicable withholding taxes. For purposes of Rule 16b-3 of the Exchange Act, Patterson's Board of Directors approved the disposition of all equity securities by the Reporting Person in connection with the merger.

F7: Represents Shares indirectly held by the Reporting Person's Employee Stock Ownership Plan component of their 401(k) (the "KSOP") account immediately prior to the closing of the Merger.

F8: Stock options granted pursuant to the Plan on 7/1/2023.

F9: This option, which vested 33.3% on 7/1/2024, and was originally scheduled to vest 33.3% on 7/1/2025 and 33.4% on 7/1/2026, was cancelled for no consideration, because the exercise price was greater than the Merger Consideration.

F10: Pursuant to the Merger Agreement, upon the closing of the Merger, each option to purchase Shares (each an "Option") outstanding and unexercised immediately prior to the closing of the Merger, whether vested or unvested, was cancelled and converted into the right to receive (without interest) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares underlying the Option multiplied by (y) the excess, if any, of the Merger Consideration over the exercise price of such Option, with any Options with a per share exercise price greater than or equal to the Merger Consideration being cancelled for no consideration.

F11: Stock options granted pursuant to the Plan on 12/5/2022.

F12: This option, which vested 33.3% on 12/5/2023, 33.3% on 12/5/2024 and was originally scheduled to vest 33.4% on 12/5/2025, was cancelled and exchanged for Merger Consideration.

F13: Stock options granted pursuant to the Plan on 7/1/2022.

F14: This option, which vested 33.3% on 7/1/2023, 33.3% on 7/1/2024 and was originally scheduled to vest 33.4% on 7/1/2025, was cancelled and exchanged for Merger Consideration.

F15: Stock options granted pursuant to the Plan on 7/1/2021.

F16: This option, which vested 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024, was cancelled and exchanged for Merger Consideration.

F17: Stock options granted pursuant to the Plan on 7/14/2020.

F18: This option, which vested 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023, was cancelled and exchanged for Merger Consideration.

F19: Stock options granted pursuant to the Plan on 7/1/2019.

F20: This option, which vested 33.3% on 7/1/2020, 33.3% on 7/1/2021 and 33.4% on 7/1/2022, was cancelled and exchanged for Merger Consideration.

F21: Stock options granted pursuant to the Plan on 7/1/2018.

F22: This option, which vested 100% on 7/1/2021, was cancelled and exchanged for Merger Consideration.

F23: Stock options granted as an inducement award granted outside the Plan on 6/29/2018.

F24: This option, which vested pro-rata over the course of 3 years, with one-third of the shares vesting on 6/29/2019, one-third vesting on 6/29/2020, and the remaining one-third vesting on 6/29/2021, in all cases subject to continued employment, was cancelled and exchanged for Merger Consideration.

ST JUDE MEDICAL, LLC

Report date January 04, 2017 · Filed January 06, 2017

Section 16 reporting ended · disclosed 2017-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-01-04 transaction · row 1 1 source row Row 1 · 2017-01-04 · Disposition to issuer · Disposed 26,075 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2018-12-14	Direct	Reported balance After 2017-01-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-01-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.96 · Expires 2019-12-12	Direct	Reported balance After 2017-01-04 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-01-04 · Disposition to issuer · Disposed 42,664 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.27 · Expires 2020-12-10	Direct	Reported balance After 2017-01-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-01-04 · Disposition to issuer · Disposed 74,664 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.41 · Expires 2021-12-10	Direct	Reported balance After 2017-01-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-01-04 · Disposition to issuer · Disposed 78,212 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.08 · Expires 2022-12-08	Direct	Reported balance After 2017-01-04 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-01-04 · Disposition to issuer · Disposed 76,440 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.62 · Expires 2023-12-07	Direct	Reported balance After 2017-01-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-01-04 · Disposition to issuer · Disposed 101,864 · Balance 0 F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-01-04 · Disposition to issuer · Disposed 2,346 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-01-04 · Disposition to issuer · Disposed 4,342 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2017-01-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-01-04 · Disposition to issuer · Disposed 8,112 · Balance 0 F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock.

F2: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes.

F3: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio.

F4: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio.

Silk Road Medical Inc

Report date September 17, 2024 · Filed September 19, 2024

Section 16 reporting ended · disclosed 2024-09-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-09-17 transaction · row 1 1 source row Row 1 · 2024-09-17 · Disposition to issuer · Disposed 12,610 · Balance 0 F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock. F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes. F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.11 · Expires 2028-03-22	Direct	Reported balance After 2024-09-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-09-17 · Disposition to issuer · Disposed 146,031 · Balance 0 F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2028-03-22	Direct	Reported balance After 2024-09-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-09-17 · Disposition to issuer · Disposed 29,206 · Balance 0 F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2029-04-03	Direct	Reported balance After 2024-09-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-09-17 · Disposition to issuer · Disposed 8,910 · Balance 0 F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Filing footnotes · ownership attribution and instrument terms

F1: Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

F2: Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

F3: Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

F4: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $3,123,603.09, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F5: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $448,312.10, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

F6: The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $66,825.00, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 05, 2022 Filed Dec 6, 2022 17:44 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	39,669	$28.99	$1,150,004.31	Disclosure SEC source: 0001209191-22-060086 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,701 F1 · kind: Represents restricted stock units ("RSU") equivalents awarded on 12/5/2022 pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan). The RSUs awarded vest, assuming continued employment, 33.3% on 12/5/2023, 33.3% on 12/5/2024 and 33.4% on 12/5/2025. F2 · balance_after: Includes an aggregate of 30,283 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020, 7/1/2021 and 7/1/2022 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 8,944 units vest 7/1/2023, 11,137 units vest 7/14/2023, 6,722 units vest 7/1/2024 and 3,480 units vest 7/1/2025. Read SEC document
July 06, 2022 Filed Jul 7, 2022 16:28 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	10,180	$29.58	$301,140.69	Disclosure SEC source: 0001209191-22-041454 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,032 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 17, 2021. F2 · balance_after: Includes an aggregate of 30,283 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020, 7/1/2021 and 7/1/2022 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 8,944 units vest 7/1/2023, 11,137 units vest 7/14/2023, 6,722 units vest 7/1/2024 and 3,480 units vest 7/1/2025. Read SEC document
July 01, 2022 Filed Jul 6, 2022 18:47 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	35,895	$30.59 Strike: $30.59	$1,098,028.05	Disclosure SEC source: 0001209191-22-041369 · doc4.xml · derivative · entry 5 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,895 Underlying: Common Stock · 35,895 shares Expires 2032-07-01 F7 · kind: Stock options granted pursuant to the Plan on 7/1/2022. F8 · derivative.exercise_date: Options are exercisable as follows: 33.3% on 7/1/2023, 33.3% on 7/1/2024 and 33.4% on 7/1/2025. Read SEC document
July 01, 2022 Filed Jul 6, 2022 18:47 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	10,420	$30.59	$318,747.80	Disclosure SEC source: 0001209191-22-041369 · doc4.xml · nonDerivative · entry 3 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,212 F5 · kind: Represents RSUs awarded on 7/1/2022 to Reporting Person pursuant to the Plan. The RSUs awarded vest, assuming continued employment, 33.3% on 7/1/2023, 33.3% on 7/1/2024 and 33.4% on 7/1/2025. F4 · balance_after: Includes an aggregate of 19,863 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020 and 7/1/2021 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 5,476 units vest 7/1/2023, 11,137 units vest 7/14/2023 and 3,250 units vest 7/1/2024. Read SEC document
July 01, 2022 Filed Jul 6, 2022 18:47 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	4,669	$30.59	$142,824.71	Disclosure SEC source: 0001209191-22-041369 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,792 F3 · kind: Represents shares of common stock withheld to satisfy a portion of tax liability upon the lapse of restrictions on RSUs issued pursuant to the Plan. F4 · balance_after: Includes an aggregate of 19,863 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020 and 7/1/2021 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon employment as follows: 5,476 units vest 7/1/2023, 11,137 units vest 7/14/2023 and 3,250 units vest 7/1/2024. Read SEC document
July 01, 2022 Filed Jul 6, 2022 18:47 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	12,294	$30.59	$376,073.46	Disclosure SEC source: 0001209191-22-041369 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,461 F1 · kind: On July 1, 2022, the restricted stock unit ("RSU") equivalents vested per the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan) and were paid out in common stock. The Company withheld shares to satisfy the tax liability associated with the vesting. F2 · balance_after: Includes an aggregate of 37,134 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020 and 7/1/2021 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 17,272 units vest 7/1/2022, 5,475 units vest 7/1/2023, 11,137 units vest 7/14/2023 and 3,250 units vest 7/1/2024. Read SEC document
June 09, 2022 Filed Jun 13, 2022 22:54 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantOption (right to buy) · Derivative	5,195	$0.00 Strike: $36.90	$0.00	Disclosure SEC source: 0001593968-22-001127 · primary_01.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,195 Underlying: Common Stock · 5,195 shares Expires 2032-06-09 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 09, 2022 Filed Jun 13, 2022 22:54 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	846	$0.00	$0.00	Disclosure SEC source: 0001593968-22-001127 · primary_01.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,060 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 08, 2022 Filed Aug 5, 2022 20:11 UTC	Sight Sciences, Inc. SGHT · Entity 5537	GrantRestricted Stock Units · Derivative	11,940	$0.00	$0.00	Disclosure SEC source: 0000899243-22-027823 · doc4.xml · derivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 Underlying: Common Stock · 11,940 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest on the earlier of (i) June 8, 2023 and (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs vest on the earlier of (i) June 8, 2023 and (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.. The RSUs have no expiration date. Read SEC document
March 15, 2022 Filed Mar 16, 2022 17:04 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	10,000	$30.88	$308,802.00	Disclosure SEC source: 0001209191-22-019277 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,755 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 17, 2021. F2 · balance_after: Includes an aggregate of 37,134 RSUs awarded on 7/1/2018, 7/1/2019, 7/14/2020 and 7/1/2021 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 17,272 units vest 7/1/2022, 5,475 units vest 7/1/2023, 11,137 units vest 7/14/2023 and 3,250 units vest 7/1/2024. F3 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
July 01, 2021 Filed Jul 6, 2021 16:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	37,831	$30.77 Strike: $30.77	$1,164,059.87	Disclosure SEC source: 0001209191-21-045504 · doc4.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,831 Underlying: Common Stock · 37,831 shares Expires 2031-07-01 F6 · kind: Stock options granted pursuant to the Plan on 7/1/2021. F7 · derivative.exercise_date: Options are exercisable as follows: 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024. Read SEC document
July 01, 2021 Filed Jul 6, 2021 16:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	9,750	$30.77	$300,007.50	Disclosure SEC source: 0001209191-21-045504 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,755 F4 · kind: Represents RSUs awarded on 7/1/2021 to Reporting Person pursuant to the Plan. The RSUs awarded vest, assuming continued employment, 33.3% on 7/1/2022, 33.3% on 7/1/2023 and 33.4% on 7/1/2024. F2 · balance_after: Includes an aggregate of 27,384 RSUs awarded on 7/1/2018, 7/1/2019 and 7/14/2020 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 14,022 units vest 7/1/2022, 2,225 units vest 7/1/2023 and 11,137 units vest 7/14/2023. F3 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
July 01, 2021 Filed Jul 6, 2021 16:42 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	892	$30.77	$27,446.84	Disclosure SEC source: 0001209191-21-045504 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,005 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued purusant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes an aggregate of 27,384 RSUs awarded on 7/1/2018, 7/1/2019 and 7/14/2020 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 14,022 units vest 7/1/2022, 2,225 units vest 7/1/2023 and 11,137 units vest 7/14/2023. F3 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
June 17, 2021 Filed Jun 21, 2021 22:38 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantOption (right to buy) · Derivative	4,066	$0.00 Strike: $50.40	$0.00	Disclosure SEC source: 0001593968-21-001670 · primary_01.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 Underlying: Common Stock · 4,066 shares Expires 2031-06-17 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 17, 2021 Filed Jun 21, 2021 22:38 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	570	$0.00	$0.00	Disclosure SEC source: 0001593968-21-001670 · primary_01.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
April 24, 2021 Filed Apr 27, 2021 17:36 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	5,630	$33.46	$188,379.80	Disclosure SEC source: 0001209191-21-028631 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,897 F1 · kind: On April 24, 2021, the restricted stock unit ("RSU") equivalents vested per the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan") and were paid out in common stock. The Company withheld shares to satisfy the tax liability associated with the vesting. F2 · balance_after: Includes an aggregate of 29,608 RSUs awarded on 7/1/2018, 7/1/2019 and 7/14/2020 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022, 2,225 units vest 7/1/2023 and 11,137 units vest 7/14/2023. F3 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
March 05, 2021 Filed Mar 9, 2021 07:40 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	SaleCommon Stock	6,817	$30.10	$205,173.29	Disclosure SEC source: 0001209191-21-018819 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,525 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 4, 2020. F2 · balance_after: Includes an aggregate of 29,608 restricted stock units ("RSUs") awarded on 7/1/2018, 7/1/2019 and 7/14/2020 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022, 2,225 units vest 7/1/2023 and 11,137 units vest 7/14/2023. F3 · balance_after: Includes 19,460 RSU equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the RSU equivalents will automatically convert into shares of common stock. F4 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
July 14, 2020 Filed Jul 16, 2020 11:51 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	57,819	$23.57 Strike: $23.57	$1,362,793.83	Disclosure SEC source: 0001209191-20-042574 · doc4.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,819 Underlying: Common Stock · 57,819 shares Expires 2030-07-14 F6 · kind: Stock options granted pursuant to the Plan on 7/14/2020. F7 · derivative.exercise_date: Options are exercisable as follows: 33.3% on 7/14/2021, 33.3% on 7/14/2022 and 33.4% on 7/14/2023. Read SEC document
July 14, 2020 Filed Jul 16, 2020 11:51 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	11,137	$23.57	$262,499.09	Disclosure SEC source: 0001209191-20-042574 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,342 F1 · kind: Represents restricted stock units ("RSUs") awarded on 7/14/2020 to Reporting Person pursuant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). The RSUs awarded vest, assuming continued employment, 100% on 7/14/2023. F2 · balance_after: Includes 18,471 RSUs awarded on 7/1/2018 and 7/1/2019 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022 and 2,225 units vest 7/1/2023. F3 · balance_after: Includes 19,460 RSU equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the RSU equivalents will automatically convert into shares of common stock. F4 · balance_after: Includes 33,625 RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
July 08, 2020 Filed Jul 11, 2020 01:10 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantOption (right to buy) · Derivative	4,482	$0.00 Strike: $44.62	$0.00	Disclosure SEC source: 0001593968-20-001622 · primary_01.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,482 Underlying: Common Stock · 4,482 shares Expires 2030-07-08 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
July 08, 2020 Filed Jul 11, 2020 01:10 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantCommon Stock	644	$0.00	$0.00	Disclosure SEC source: 0001593968-20-001622 · primary_01.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644 F1 · shares: The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of SILK common stock. All of the RSUs vest on the earlier of (i) the one-year anniversary of the date the award is granted or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:59 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	33,625	$22.32	$750,510.00	Disclosure SEC source: 0001209191-20-041383 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,205 F4 · kind: Represents RSU equivalents attributable to the July 1, 2020 determination by the Compensation Committee that the performance criteria for the period of April 27, 2019 through April 25, 2020 applicable to non-derivative performance units issued on July 1, 2019 had been satisfied. Subject to continued employment of the Reporting Person through July 1, 2022, the RSU equivalents will automatically convert into shares of common stock. F2 · balance_after: Includes 18,471 RSUs awarded on 7/1/2018 and 7/1/2019 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022 and 2,225 units vest 7/1/2023. F3 · balance_after: Includes 19,460 RSU equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
July 01, 2020 Filed Jul 6, 2020 20:59 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	537	$22.32	$11,985.84	Disclosure SEC source: 0001209191-20-041383 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,580 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued purusant to the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes 18,471 RSUs awarded on 7/1/2018 and 7/1/2019 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022 and 2,225 units vest 7/1/2023. F3 · balance_after: Includes 19,460 RSU equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
June 29, 2020 Filed Jun 30, 2020 13:30 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	3,734	$22.50	$84,015.00	Disclosure SEC source: 0001209191-20-039413 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,117 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued 6/29/2018 outside the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes 20,695 RSUs awarded on 7/1/2018 and 7/1/2019 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2020, 2,224 units vest 7/1/2021, 14,022 units vest 7/1/2022 and 2,225 units vest 7/1/2023. F3 · balance_after: Includes 19,460 RSU equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the RSU equivalents will automatically convert into shares of common stock. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:39 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerRestricted Stock Units · Derivative	3,005	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-057947 · doc4.xml · derivative · entry 5 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,005 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · price: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F4 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. F4 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("Issuer RSU") (excluding any Issuer RSU that vested prior to or as a result of the consummation of the Merger and which settled in shares of Issuer Common Stock that were converted into the right to receive shares of Parent Common Stock as a result of the Merger) was assumed by Parent and converted into the right to receive shares of Parent Common Stock (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such Issuer RSU. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:39 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerStock Option (right to buy) · Derivative	10,224	Not disclosed Strike: $3.69	Not disclosed	Disclosure SEC source: 0001209191-19-057947 · doc4.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,224 shares Expires 2028-07-17 F2 · price: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. F2 · derivative.exercise_date: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:39 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerStock Option (right to buy) · Derivative	41,941	Not disclosed Strike: $2.67	Not disclosed	Disclosure SEC source: 0001209191-19-057947 · doc4.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,941 shares Expires 2027-06-26 F2 · price: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. F2 · derivative.exercise_date: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:39 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerStock Option (right to buy) · Derivative	8,314	Not disclosed Strike: $12.73	Not disclosed	Disclosure SEC source: 0001209191-19-057947 · doc4.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,314 shares Expires 2029-01-08 F2 · price: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. F2 · derivative.exercise_date: At the Effective Time, each outstanding and unexercised option to purchase Issuer Common Stock (whether vested or unvested) immediately prior to the Effective Time, was assumed by Parent and converted into an option to purchase shares of Parent Common Shares (rounded down to the nearest whole share) using a conversion ratio designed to preserve the intrinsic value of such option of Issuer. Certain of the options may be settled in cash based on the extent, if any, to which the fair market value of the shares underlying the options at the time of exercise exceeds the applicable exercise price of the options. Read SEC document
November 21, 2019 Filed Nov 25, 2019 21:39 UTC	AVEDRO INC AVDR · Entity 153528	Disposition to issuerCommon Stock	3,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-057947 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated as of August 7, 2019, by and among Avedro, Inc. (the "Issuer"), Glaukos Corporation ("Parent") and Atlantic Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), on November 21, 2019, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer continuing as the surviving corporation. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock of the Issuer ("Issuer Common Stock") that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive 0.365 of a share of Parent's common stock ("Parent Common Stock"). The closing price of shares of the Parent Common Stock on November 21, 2019 was $63.07 per share. Read SEC document
July 01, 2019 Filed Jul 2, 2019 17:11 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantEmployee Stock Options · Derivative	78,829	$22.25 Strike: $22.25	$1,753,945.25	Disclosure SEC source: 0001209191-19-040434 · doc4.xml · derivative · entry 5 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,829 Underlying: Common Stock · 78,829 shares Expires 2029-07-01 F8 · kind: Stock options granted pursuant to the Plan on 7/1/2019. F9 · derivative.exercise_date: Options are exercisable as follows: 33% on 7/1/2020, 33% on 7/1/2021 and 34% on 7/1/2022. Read SEC document
July 01, 2019 Filed Jul 2, 2019 17:11 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	11,798	$22.25	$262,505.50	Disclosure SEC source: 0001209191-19-040434 · doc4.xml · nonDerivative · entry 3 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,391 F6 · kind: Represents RSUs awarded on 7/1/2019 to Reporting Person pursuant to the Plan. The RSUs awarded vest, assuming continued employment, 100% on 7/1/2022. F3 · balance_after: Includes 15,439 RSUs granted to Reporting Person on 6/29/2018 as an inducement award granted outside the Plan. The RSUs will vest, assuming continued employment, on 6/9/2020. F5 · balance_after: Includes 8,897 RSUs awarded on 7/1/2018 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2020, 2,224 units vest 7/1/2021, 2,224 units vest 7/1/2022 and 2,225 units vest 7/1/2023. Read SEC document
July 01, 2019 Filed Jul 2, 2019 17:11 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	681	$22.25	$15,152.25	Disclosure SEC source: 0001209191-19-040434 · doc4.xml · nonDerivative · entry 2 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,593 F4 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on RSUs issued pursuant to the Plan. F3 · balance_after: Includes 15,439 RSUs granted to Reporting Person on 6/29/2018 as an inducement award granted outside the Plan. The RSUs will vest, assuming continued employment, on 6/9/2020. F5 · balance_after: Includes 8,897 RSUs awarded on 7/1/2018 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2020, 2,224 units vest 7/1/2021, 2,224 units vest 7/1/2022 and 2,225 units vest 7/1/2023. Read SEC document
June 29, 2019 Filed Jul 2, 2019 17:11 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	Tax withholdingCommon Stock	4,725	$22.90	$108,202.50	Disclosure SEC source: 0001209191-19-040434 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,274 F1 · kind: Represents shares of common stock withheld for payment of taxes incurred upon the lapse of restrictions on restricted stock units ("RSUs") issued 6/29/2018 outside the Patterson Companies, Inc. Amended and Restated 2015 Omnibus Incentive Plan ("Plan"). F2 · balance_after: Includes 11,121 RSUs awarded on 7/1/2018 to Reporting Person pursuant to the Plan. The RSUs vest contingent upon continued employment as follows: 2,224 units vest 7/1/2019, 2,224 units vest 7/1/2020, 2,224 units vest 7/1/2021, 2,224 units vest 7/1/2022 and 2,225 units vest 7/1/2023. F3 · balance_after: Includes 15,439 RSUs granted to Reporting Person on 6/29/2018 as an inducement award granted outside the Plan. The RSUs will vest, assuming continued employment, on 6/9/2020. Read SEC document
June 14, 2019 Filed Jun 18, 2019 23:56 UTC	AVEDRO INC AVDR · Entity 153528	GrantRestricted Stock Units · Derivative	3,005	$0.00	$0.00	Disclosure SEC source: 0001209191-19-037853 · doc4.xml · derivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date. F2 · derivative.expiration_date: The RSUs vest on June 1, 2020, subject to Reporting Person's continuous service through such date. Read SEC document
June 11, 2019 Filed May 7, 2020 18:17 UTC	PATTERSON COMPANIES, INC. PDCO · Entity 80730	GrantCommon Stock	19,460	$0.00	$0.00	Disclosure SEC source: 0001209191-20-027779 · doc5.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,851 F1 · shares: Represents restricted stock unit equivalents attributable to the June 11, 2019 determination by the Compensation Committee that the performance criteria for the period of April 29, 2018 through April 27, 2019 applicable to non-derivative performance units issued on August 7, 2018 had been satisfied. Subject to continued employment of the Reporting Person through April 24, 2021, the restricted stock unit equivalents will automatically convert into shares of common stock. Because the restricted stock unit equivalents are payable solely in shares of common stock, the award is being reported on Table I. Read SEC document
April 03, 2019 Filed Apr 6, 2019 01:33 UTC	Silk Road Medical Inc SILK · Entity 87417	GrantDirector Stock Option (Right to buy) · Derivative	8,910	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001628280-19-003990 · wf-form4_155451438010756.xml · derivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,910 Underlying: Common Stock · 8,910 shares Expires 2029-04-03 F1 · derivative.exercise_date: One third of the shares subject to the option shall vest on May 3, 2020 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
February 19, 2019 Filed Feb 20, 2019 00:20 UTC	AVEDRO INC AVDR · Entity 153528	GrantStock Option (right to buy) · Derivative	8,314	$0.00 Strike: $12.73	$0.00	Disclosure SEC source: 0001209191-19-011349 · doc4.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,314 Underlying: Common Stock · 8,314 shares Expires 2029-01-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (x) June 1, 2020 and (y) the first anniversary of the first annual meeting of the Issuer's stockholders following the Issuer's initial public offering, subject to the Reporting Person continuing to provide service through such date. Read SEC document
February 19, 2019 Filed Feb 20, 2019 00:20 UTC	AVEDRO INC AVDR · Entity 153528	PurchaseCommon Stock	3,500	$14.00	$49,000.00	Disclosure SEC source: 0001209191-19-011349 · doc4.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	8,112	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 10 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,112 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	101,864	Not disclosed Strike: $61.62	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 9 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,864 shares Expires 2023-12-07 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	4,342	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 8 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,342 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	76,440	Not disclosed Strike: $69.08	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 7 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,440 shares Expires 2022-12-08 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerRestricted Stock Units · Derivative	2,346	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 6 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,346 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · price: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	78,212	Not disclosed Strike: $59.41	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 5 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,212 shares Expires 2021-12-10 F3 · price: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. F3 · derivative.exercise_date: Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table. Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2). The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	74,664	Not disclosed Strike: $35.27	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 4 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,664 shares Expires 2020-12-10 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	42,664	Not disclosed Strike: $34.96	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 3 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,664 shares Expires 2019-12-12 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerStock Options (Right to Buy) · Derivative	30,000	Not disclosed Strike: $41.65	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · derivative · entry 2 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2018-12-14 F2 · price: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock ("Net Exercise Shares") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes. Read SEC document
January 04, 2017 Filed Jan 6, 2017 13:01 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Disposition to issuerCommon Stock	26,075	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-000576 · edgar.xml · nonDerivative · entry 1 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories ("Abbott"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the "Merger Agreement"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the "Merger Consideration"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 17:40 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	2,704	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033324 · edgar.xml · derivative · entry 12 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,112 Underlying: Common Stock · 10,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document
December 17, 2016 Filed Dec 20, 2016 17:40 UTC	ST JUDE MEDICAL, LLC STJ · Entity 179857	Exercise / conversionRestricted Stock Units · Derivative	2,171	$0.00	$0.00	Disclosure SEC source: 0001179110-16-033324 · edgar.xml · derivative · entry 11 Zurbay Donald · CIK 0001341608 · VP Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,342 Underlying: Common Stock · 6,513 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · derivative.exercise_date: The restricted stock units will vest 25% on December 17th annually beginning the date shown. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.